Literature DB >> 28658489

Association of Electroconvulsive Therapy With Psychiatric Readmissions in US Hospitals.

Eric P Slade1, Danielle R Jahn2, William T Regenold3, Brady G Case4.   

Abstract

Importance: Although electroconvulsive therapy (ECT) is considered the most efficacious treatment available for individuals with severe affective disorders, ECT's availability is limited and declining, suggesting that information about the population-level effects of ECT is needed. Objective: To examine whether inpatient treatment with ECT is associated with a reduction in 30-day psychiatric readmission risk in a large, multistate sample of inpatients with severe affective disorders. Design, Setting, and Participants: A quasi-experimental instrumental variables probit model of the association correlation of ECT administration with patient risk of 30-day readmission was estimated using observational, longitudinal data on hospital inpatient discharges from US general hospitals in 9 states. From a population-based sample of 490 252 psychiatric inpatients, a sample was drawn that consisted of 162 691 individuals with a principal diagnosis of major depressive disorder (MDD), bipolar disorder, or schizoaffective disorder. The key instrumental variable used in the analysis was ECT prevalence in the prior calendar year at the treating hospital. To examine whether ECT's association with readmissions was heterogeneous across population subgroups, analyses included interactions of ECT with age group, sex, race/ethnicity, and diagnosis group. The study was conducted from August 27, 2015, to March 7, 2017. Main Outcome and Measures: Readmission within 30 days of being discharged.
Results: Overall, 2486 of the 162 691 inpatients (1.5%) underwent ECT during their index admission. Compared with other inpatients, those who received ECT were older (mean [SD], 56.8 [16.5] vs 45.9 [16.5] years; P < .001) and more likely to be female (65.0% vs 54.2%; P < .001) and white non-Hispanic (85.3% vs 62.1%; P < .001), have MDD diagnoses (63.8% vs 32.0%; P < .001) rather than bipolar disorder (29.0% vs 40.0%; P < .001) or schizoaffective disorder (7.1% vs 28.0%; P < .001), have a comorbid medical condition (31.3% vs 26.6%; P < .001), have private (39.4% vs 21.7%; P < .001) or Medicare (49.2% vs 39.4%; P < .001) insurance coverage, and be located in urban small hospitals (31.2% vs 22.3%; P < .001) or nonurban hospitals (9.0% vs 7.6%; P = .02). Administration of ECT was associated with a reduced 30-day readmission risk among psychiatric inpatients with severe affective disorders from an estimated 12.3% among individuals not administered ECT to 6.6% among individuals administered ECT (risk ratio [RR], 0.54; 95% CI, 0.28-0.81). Significantly larger associations with ECT on readmission risk were found for men compared with women (RR, 0.44; 95% CI, 0.20-0.69 vs 0.58; 95% CI, 0.30-0.88) and for individuals with bipolar disorder (RR, 0.42; 95% CI, 0.17-0.69) and schizoaffective disorder (RR, 0.44; 95% CI, 0.11-0.79) compared with those who had MDD (RR, 0.53; 95% CI, 0.26-0.81). Conclusions and Relevance: Electroconvulsive therapy may be associated with reduced short-term psychiatric inpatient readmissions among psychiatric inpatients with severe affective disorders. This potential population health effect may be overlooked in US hospitals' current decision making regarding the availability of ECT.

Entities:  

Mesh:

Year:  2017        PMID: 28658489      PMCID: PMC5710550          DOI: 10.1001/jamapsychiatry.2017.1378

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  26 in total

1.  Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods.

Authors:  Thérèse A Stukel; Elliott S Fisher; David E Wennberg; David A Alter; Daniel J Gottlieb; Marian J Vermeulen
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Reimbursement and documentation issues in an ambulatory ECT program.

Authors:  S Bailine
Journal:  J ECT       Date:  1998-12       Impact factor: 3.635

3.  Hospital readmission among medicaid patients with an index hospitalization for mental and/or substance use disorder.

Authors:  Tami L Mark; Tami Mark; Karen Smoyer Tomic; Niranjana Kowlessar; Bong Chul Chu; Rita Vandivort-Warren; Shelagh Smith
Journal:  J Behav Health Serv Res       Date:  2013-04       Impact factor: 1.505

4.  Declining use of electroconvulsive therapy in United States general hospitals.

Authors:  Brady G Case; David N Bertollo; Eugene M Laska; Lawrence H Price; Carole E Siegel; Mark Olfson; Steven C Marcus
Journal:  Biol Psychiatry       Date:  2012-10-08       Impact factor: 13.382

5.  A framework for the study of access to medical care.

Authors:  L A Aday; R Andersen
Journal:  Health Serv Res       Date:  1974       Impact factor: 3.402

Review 6.  Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies.

Authors:  J Greenhalgh; C Knight; D Hind; C Beverley; S Walters
Journal:  Health Technol Assess       Date:  2005-03       Impact factor: 4.014

7.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

8.  Mortality in depressed patients treated with electroconvulsive therapy and antidepressants.

Authors:  D Avery; G Winokur
Journal:  Arch Gen Psychiatry       Date:  1976-09

9.  Racial disparity in the use of ECT for affective disorders.

Authors:  William R Breakey; Gary J Dunn
Journal:  Am J Psychiatry       Date:  2004-09       Impact factor: 18.112

10.  Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment.

Authors:  Helle K Schoeyen; Ute Kessler; Ole A Andreassen; Bjoern H Auestad; Per Bergsholm; Ulrik F Malt; Gunnar Morken; Ketil J Oedegaard; Arne Vaaler
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

View more
  27 in total

1.  Modified Anesthesia Protocol for Electroconvulsive Therapy Permits Reduction in Aerosol-Generating Bag-Mask Ventilation during the COVID-19 Pandemic.

Authors:  James Luccarelli; Claudia Fernandez-Robles; Carlos Fernandez-Robles; Ryan J Horvath; Sheri Berg; Thomas H McCoy; Stephen J Seiner; Michael E Henry
Journal:  Psychother Psychosom       Date:  2020-06-18       Impact factor: 17.659

2.  Electroconvulsive practice in Singapore: a cross-sectional national survey.

Authors:  Phern-Chern Tor; Verònica Gálvez; Aaron Ang; Johnson Fam; Herng-Nieng Chan; Sheng-Neng Tan; Colleen K Loo
Journal:  Singapore Med J       Date:  2019-06-14       Impact factor: 1.858

Review 3.  [Rationality and freedom in medicine: the case of electroconvulsive therapy].

Authors:  U Wiesing; A J Fallgatter
Journal:  Nervenarzt       Date:  2018-11       Impact factor: 1.214

4.  ECT in a time of COVID-19.

Authors:  Phern Chern Tor; Adeline H H Phu; Doris S H Koh; Yee Ming Mok
Journal:  J ECT       Date:  2020-03-31       Impact factor: 3.635

5.  Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States.

Authors:  Eric L Ross; Kara Zivin; Daniel F Maixner
Journal:  JAMA Psychiatry       Date:  2018-07-01       Impact factor: 21.596

6.  Patient-level Characteristics and Inequitable Access to Inpatient Electroconvulsive Therapy for Depression: A Population-based Cross-sectional Study: Caractéristiques au niveau du patient et accès inéquitable à la thérapie électroconvulsive pour patients hospitalisés.

Authors:  Tyler S Kaster; Daniel M Blumberger; Tara Gomes; Rinku Sutradhar; Zafiris J Dasklakis; Duminda N Wijeysundera; Simone N Vigod
Journal:  Can J Psychiatry       Date:  2020-07-02       Impact factor: 4.356

7.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

8.  Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans.

Authors:  Samuel T Wilkinson; Edeanya Agbese; Douglas L Leslie; Robert A Rosenheck
Journal:  Psychiatr Serv       Date:  2018-02-01       Impact factor: 3.084

9.  A Quasi-Experimental Analysis of Lethal Means Assessment and Risk for Subsequent Suicide Attempts and Deaths.

Authors:  Jennifer M Boggs; Arne Beck; Debra P Ritzwoller; Catherine Battaglia; Heather D Anderson; Richard C Lindrooth
Journal:  J Gen Intern Med       Date:  2020-02-10       Impact factor: 5.128

10.  Treatment Capacity and Clinical Outcomes for Patients With Schizophrenia Who Were Treated With Electroconvulsive Therapy: A Retrospective Cohort Study.

Authors:  Joanne E Plahouras; Gerasimos Konstantinou; Tyler S Kaster; Daniel Z Buchman; George Foussias; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.